--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-037122" form_type: "8-K" ticker: "AYTU" cik: "0001385818" company_name: "AYTU BIOPHARMA, INC" filed_at: "2023-03-27T23:59:59+00:00" generated_at: "2026-06-17T14:39:17.501262+00:00" event_type: "debt" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # Aytu BioPharma increases Eclipse revolving credit facility by $2M to $14.5M ## Summary - Eclipse Amendment No. 4 increased revolving loan commitment by $2M, total facility now $14.5M. - Borrowing remains subject to borrowing base and reserve requirements. - Avenue Amendment permits the Eclipse facility increase; no other terms changed. - Loan agreements dated back to 2019; amendments align with existing debt structure. ## SEC filing metadata - accession: 0001104659-23-037122 - form_type: 8-K - ticker: AYTU - cik: 0001385818 - company_name: AYTU BIOPHARMA, INC - filed_at: 2023-03-27T23:59:59+00:00 - event_type: debt - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 1.01, 2.03 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/0001104659-23-037122-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/tm2310570d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-037122 - JSON: https://secwatch.observer/filing/0001104659-23-037122.json - Plain text: https://secwatch.observer/filing/0001104659-23-037122.txt ## Key facts - Debt Financings AYTU BIOPHARMA, INC amended revolving credit of Increase of $2,000,000 to revolving loan commitment, resulting in aggregate revolving facility size of $14,500,000 with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and the lenders party thereto at Not specified maturing Not specified. - Instrument: revolving credit - Principal: Increase of $2,000,000 to revolving loan commitment, resulting in aggregate revolving facility size of $14,500,000 - Counterparty: Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and the lenders party thereto - Rate: Not specified - Maturity: Not specified - Event: amendment source text: and the lenders party thereto (agent and such lenders, collectively, the “ Eclipse Lender ”). The Eclipse Amendment, among other things, provided for an aggregate increase of $2,000,000 to the Eclipse Lender’s commitment to make revolving loans from time to time to the Neos Obligors, resulting in an aggregate revolving facility size of $14,500,000 (such facility, evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/0001104659-23-037122-index.htm - Debt Financings AYTU BIOPHARMA, INC amended credit facility of No change in principal amount; amendment permitted the increase in revolving loan commitment under the Eclipse Facility with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders, and Avenue Capital Management II, L.P. as administrative agent at Not specified maturing Not specified. - Instrument: credit facility - Principal: No change in principal amount; amendment permitted the increase in revolving loan commitment under the Eclipse Facility - Counterparty: Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders, and Avenue Capital Management II, L.P. as administrative agent - Rate: Not specified - Maturity: Not specified - Event: amendment source text: In connection with the Eclipse Amendment, on March 24, 2023, the Obligors entered into the Second Amendment to Loan Documents (the “ Avenue Amendment ”) amending that certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022, the “ Avenue Agreement ”), by and among the Obligors, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P., as lenders (the “ Avenue Capital Lenders ”), and Avenue Capital Management II, L.P., as administrative agent (the “ Avenue Capital Agent ”). The Avenue Amendment, among other things, permitted the increase in revolving loan commitment provided by the Eclipse Lender under the Eclipse Facility as provided for in the Eclipse Amendment. evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/0001104659-23-037122-index.htm - Material Agreements AYTU BIOPHARMA, INC amended Avenue Amendment with Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P. (effective 2023-03-24). - Action: amendment - Agreement: credit facility - Counterparty: Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P. - Effective: 2023-03-24 source text: In connection with the Eclipse Amendment, on March 24, 2023, the Obligors entered into the Second Amendment to Loan Documents (the “ Avenue Amendment ”) amending that certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022, the “ Avenue Agreement ”) evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/0001104659-23-037122-index.htm - Material Agreements AYTU BIOPHARMA, INC amended Eclipse Amendment with Eclipse Business Capital LLC, as agent, and the lenders party thereto valued at aggregate increase of $2,000,000 (effective 2023-03-24). - Action: amendment - Agreement: credit facility - Counterparty: Eclipse Business Capital LLC, as agent, and the lenders party thereto - Value: aggregate increase of $2,000,000 - Effective: 2023-03-24 source text: On March 24, 2023, Aytu BioPharma, Inc. (“ Aytu ” or the “ Company ”) entered into an Amendment No. 4 (the “ Eclipse Amendment ”) to Loan and Security Agreement dated October 2, 2019 evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/0001104659-23-037122-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.